Call for comments no later than Friday, 16 April 2021
The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, the University of Texas Medical Branch (UTMB), an expert team of taskforce members from around the world, and the World Health Organization (WHO) have developed a draft Zika virus (ZIKV) Research and Development (R&D) Roadmap.The roadmap is a key component of the WHO’s R&D Blueprint, a global strategy and preparedness plan that allows the activation of R&D activities in advance of and during epidemics.
The purpose of the roadmap is to accelerate the development and implementation of effective medical countermeasures for ZIKV aimed at reducing morbidity, mortality, and transmission. The roadmap identifies the vision, strategic goals, and aligned milestones aimed at developing effective diagnostics, therapeutic agents, and vaccines for ZIKV.
Please provide comments following the instructions below. Kindly note that you can either provide input on the entire document or only on certain parts. Comments may be publicly disclosed at a later stage of the review process; submission of comments will be considered as permission to publicly disclose feedback received. Comments should be submitted in English. Input received from this consultation will contribute to the further development and finalization of the roadmap.
The Zika virus (ZIKV) Research and Development (R&D) Roadmap is now open for comments.